Discover
QNCX
Quince Therapeutics, Inc.
18.78
1 x 18.00
1 x 19.62
bid
ask
+
0.00
0.00%
09:27 AM
timesize
| Ytd | -97.20% | |
| 1y | -94.69% |
18.74
day range
18.74
16.00
52 week range
880.00
| Open | 18.74 | Prev Close | 18.78 | Low | 18.74 | High | 18.74 | Mkt Cap | 5.23M |
| Vol | 361.00 | Avg Vol | 59.47K | EPS | -106.20 | P/E | -0.18 | Forward P/E | -5.68 |
| Beta | 1.40 | Short Ratio | 2.27 | Inst. Own | 25.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 20.08 | 200-d Avg | 229.00 | 1yr Est | 9.00 |
| Income Statement | |||
| Operating Expenses | 78.92M | ||
| Research and Development Expense | 6.85M | ||
| Selling, General and Administrative Expense | 4.27M | ||
| Operating Income | -78.92M | ||
| Income Tax Expense | -5.34M | ||
| Net Income | 35.91M | ||
| Net Income Common Stock | 35.91M | ||
| Net Income Common Stock (USD) | 35.91M | ||
| Consolidated Income | 35.91M | ||
| Earnings per Basic Share | 72.00 | ||
| Earnings per Basic Share (USD) | 72.00 | ||
| Earnings per Diluted Share | 58.00 | ||
| Earning Before Interest & Taxes (EBIT) | 30.57M | ||
| Earning Before Interest & Taxes (USD) | 30.57M | ||
| Weighted Average Shares | 456.01K | ||
| Weighted Average Shares Diluted | 459.52K | ||
| Balance Sheet | |||
| Cash and Equivalents | 18.16M | ||
| Cash and Equivalents (USD) | 18.16M | ||
| Current Assets | 25.58M | ||
| Property, Plant & Equipment Net | 965.00K | ||
| Total Assets | 26.62M | ||
| Total Debt | 293.00K | ||
| Current Liabilities | 8.77M | ||
| Debt Non-Current | 293.00K | ||
| Total Liabilities | 10.95M | ||
| Accumulated Retained Earnings (Deficit) | -424.54M | ||
| Accumulated Other Comprehensive Income | 4.61M | ||
| Shareholders Equity | 15.67M | ||
| Shareholders Equity (USD) | 15.67M | ||
| Assets Non-Current | 1.04M | ||
| Total Debt (USD) | 293.00K | ||
| Liabilities Non-Current | 2.18M | ||
| Trade and Non-Trade Payables | 5.39M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 36.00K | ||
| Net Cash Flow from Financing | 9.44M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 12.35M | ||
| Issuance (Purchase) of Equity Shares | 14.99M | ||
| Issuance (Repayment) of Debt Securities | -5.54M | ||
| Net Cash Flow from Investing | 12.00M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 12.00M | ||
| Net Cash Flow from Operations | -7.63M | ||
| Effect of Exchange Rate Changes on Cash | -1.46M | ||
| Share Based Compensation | 1.29M | ||